A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53785#.VNMYRizQrzE Author(s) Tetsu Yamamoto 1* , Ryoji Hyakudomi 1 , Shinichi Sugimoto 2 , Atsuo Tokuka 2 , Yoshitoshi Sato 3 , Satoshi Nagai 4 , Hikota Hayashi 1 , Masahikoo Igarashi 5 , Kenji Takubo 3 , Yoshitsugu Tajima 1 Affiliation(s) 1 Department of Digestive and General Surgery, Faculty of Medicine, Shimane University, Izumo, Japan . 2 Department of Surgery, Shimane Prefectural Central Hospital, Izumo, Japan . 3 Department of Gastroenterological Surgery, Matsue Red Cross Hospital, Matsue, Japan . 4 Department of Surgery, National Hospital Organization Hamada Medical Center, Hamada, Japan . 5 Department of Surgery, Masuda Medical Association Hospital, Masuda, Japan . ABSTRACT Oxaliplatin-based chemotherapy with bevacizumab is now widely used for colorectal cancer patients. This study evaluated the efficacy and tolerability of XELOX (capecitabine + o...